MSD supports Our Future Health, the UK’s largest ever health research programme, as a founding Industry Member
January 18, 2022 11:37 am +00:00
EMBARGOED FOR RELEASE UNTIL Tuesday, 18 JANUARY, 2022, 9:00 GMT
MSD supports Our Future Health, the UK’s largest ever health research programme, as a founding Industry Member
LONDON JANUARY 18, 2022 – MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK))announced today its founding industry member support for Our Future Health, the UK’s largest ever health research programme, which aims to transform the detection, prevention and treatment of a wide range of diseases.
Our Future Health aims to recruit five million adult volunteers, from all backgrounds, to participate in the research programme. By joining the voluntary research programme, people will be able to contribute to the most comprehensive picture of health ever captured in the UK.
In joining the research programme, voluntary participants will be contributing to vital research to develop new ways to prevent, detect and treat diseases and health conditions such as cancer, Alzheimer’s and heart disease. A key focus will be developing approaches for identifying diseases such as cancer and heart disease before they become symptomatic.
Researchers from across academia, industry and the NHS will be able to apply to use Our Future Health data and samples for their crucial research.
MSD will be contributing both expertise and funding. Through participation in Our Future Health, MSD is committed to improving the scientific understanding of human disease and risk factors for disease.
Senior Vice President and Head of Discovery Sciences and Translational Medicine at MSD, Dr Fiona Marshall, said:
“We’re delighted to be one of the founding partners of Our Future Health. This offers a unique opportunity to understand the drivers of disease which will ultimately lead to better options for prevention and treatment.”
Dr Victor Neduva, Senior Director, Discovery Research at MSD, based in London, said:
“At MSD, we’re passionate about innovating for patients. We’re proud to be founding members of Our Future Health and committed to what can be achieved through this ambitious UK research programme.”
Our Future Health has initially invited 5,000 members of the public to join the pilot phase of the programme in partnership with NHS Blood and Transplant, before expanding recruitment across the UK from Spring 2022.
To register for news and updates about volunteering to join Our Future Health from next year visit www.ourfuturehealth.org.uk to join the mailing list.
About MSD
For more than 125 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd-uk.com and connect with us @MSDintheUK on Twitter, Instagram, LinkedIn, YouTube and Facebook.
GB-NON-05458 | Date of Preparation: January 2022